Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima
Madan, Ravi Amrit
Theoret, Marc Robert
Arlen, Philip M.
Strauss, Julius
Chun, Guinevere
Couvillon, Anna
Harold, Nancy
Chen, Clara
Dawson, Nancy Ann
Apolo, Andrea Borghese
Steinberg, Seth M.
Trepel, Jane B.
Wright, John Joseph
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NCI, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA
[5] NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD USA
[6] Lombardi Comprehens Canc Ctr, Washington, DC USA
[7] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[8] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[9] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[10] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).
    Pouessel, Damien
    Terrisse, Safae Aarab
    Mouillet, Guillaume
    Breitkopf, Katharina
    Theodore, Christine
    Lobbedez, Florence Joly
    Roubaud, Guilhem
    Flechon, Aude
    Tourani, Jean-Marc
    Massard, Christophe
    Thiery-Vuillemin, Antoine
    Oudard, Stephane
    Sevin, Emmanuel
    Chevret, Sylvie
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] PSA response and cabazitaxel outcomes stratified by prior docetaxel PSA response in metastatic castrate-resistant prostate cancer (mCRPC).
    Wee, Christopher Eing
    Nizam, Amanda
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Chen, Xiaoying
    Maroli, Kimberly
    Martin, Allison
    Bonham, Amanda
    Pietro, Carolyn
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 119 - 119
  • [33] Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [34] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
  • [36] Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
    Cornford, Philip
    JOURNAL OF CLINICAL UROLOGY, 2010, 3 (06) : 225 - 230
  • [37] Bevacizumab andWeekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
    Francini, Filippo
    Pascucci, Alessandra
    Francini, Edoardo
    Bargagli, Gianluca
    Conca, Raffaele
    Licchetta, Antonella
    Roviello, Giandomenico
    Martellucci, Ignazio
    Chiriaco, Giorgio
    Miano, Salvatora Tindara
    Marzocca, Giuseppe
    Manganelli, Antonio
    Ponchietti, Roberto
    Savelli, Vinno
    Petrioli, Roberto
    PROSTATE CANCER, 2011, 2011
  • [38] Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
    Vaishampayan, Ulka N.
    Podgorski, Izabela
    Heilbrun, Lance K.
    Smith, Daryn W.
    Lawhorn-Crews, Jawana
    Dobson, Kimberlee
    Fontana, Joseph A.
    Heath, Elisabeth I.
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [39] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [40] A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru P.
    Das, Devika
    Bitting, Rhonda L.
    Berry, William
    Healy, Patrick
    Anand, Monika
    Winters, Carol
    Riggan, Colleen
    Kephart, Julie
    Wilder, Rhonda
    Shobe, Kellie
    Rasmussen, Julia
    Milowsky, Matthew I.
    Fleming, Mark T.
    Bearden, James
    Goodman, Michael
    Zhang, Tian
    Harrison, Michael R.
    McNamara, Megan
    Zhang, Dadong
    LaCroix, Bonnie L.
    Kittles, Rick A.
    Patierno, Brendon M.
    Sibley, Alexander B.
    Patierno, Steven R.
    Owzar, Kouros
    Hyslop, Terry
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    CANCER, 2021, 127 (16) : 2954 - 2965
12345